Roivant Sciences (87S) Stock Forecast & Price Target

Compare

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

87S Analyst Ratings

Strong Buy

7 Buy

1 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Roivant

Sciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

87S Stock 12 Month Forecast

Average Price Target

€18.60

▲(10.58% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Roivant Sciences in the last 3 months. The average price target is €18.60 with a high forecast of €21.69 and a low forecast of €14.31. The average price target represents a 10.58% change from the last price of €16.82.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"€8","15":"€15","22":"€22","11.5":"€11.5","18.5":"€18.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21.688756,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€21.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.6002771456,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€18.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.31457896,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€14.31</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,11.5,15,18.5,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.455,13.165288923076924,13.875577846153845,14.585866769230769,15.296155692307693,16.006444615384616,16.71673353846154,17.427022461538463,18.137311384615387,18.84760030769231,19.55788923076923,20.268178153846154,20.978467076923078,{"y":21.688756,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.455,12.927713626584616,13.40042725316923,13.873140879753846,14.345854506338462,14.818568132923076,15.291281759507692,15.763995386092308,16.236709012676922,16.70942263926154,17.182136265846154,17.654849892430768,18.127563519015382,{"y":18.6002771456,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.455,12.598044535384615,12.741089070769231,12.884133606153846,13.027178141538462,13.170222676923077,13.313267212307693,13.456311747692308,13.599356283076924,13.742400818461538,13.885445353846155,14.02848988923077,14.171534424615386,{"y":14.31457896,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.545,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.525,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.815,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.435,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.576,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.21,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.778,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.34,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.366,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.496,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.06,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.455,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€21.69

Average Price Target€18.60

Lowest Price Target€14.31

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Samantha Semenkow

Citi

€13.88→€21.69

Buy

28.95%

Upside

Reiterated

10/30/25

Roivant Sciences price target raised to $25 from $16 at CitiRoivant Sciences price target raised to $25 from $16 at Citi

Brian Cheng

J.P. Morgan

€17.35

Buy

3.16%

Upside

Reiterated

10/08/25

J.P. Morgan Reaffirms Their Buy Rating on Roivant Sciences (ROIV)

Corinne Johnson

Goldman Sachs

€20.82

Buy

23.79%

Upside

Reiterated

09/30/25

Goldman Sachs Sticks to Their Buy Rating for Roivant Sciences (ROIV)

David Risinger

Leerink Partners

€15.62→€19.09

Buy

13.47%

Upside

Reiterated

09/29/25

Analysts Offer Insights on Healthcare Companies: Roivant Sciences (NASDAQ: ROIV), Climb Bio (NASDAQ: CLYM) and Crinetics Pharmaceuticals (NASDAQ: CRNX)

Chi Meng Fong

Bank of America Securities

€14.31

Hold

-14.90%

Downside

Reiterated

09/24/25

Hold Rating for Roivant Sciences Amid Promising Developments and Competitive Challenges

Yaron Werber

TD Cowen

€19.95

Buy

18.63%

Upside

Reiterated

09/18/25

Yaron Werber's Buy Rating Highlights Brepocitinib's Potential as a Leading Treatment for Dermatomyositis

Douglas Tsao

H.C. Wainwright

€15.62→€17.35

Buy

3.16%

Upside

Reiterated

09/18/25

H.C. Wainwright Reaffirms Their Buy Rating on Roivant Sciences (ROIV)

Yatin Suneja

Guggenheim

€13.01→€18.22

Buy

8.31%

Upside

Reiterated

09/17/25

Guggenheim Keeps Their Buy Rating on Roivant Sciences (ROIV)

Prakhar Agrawal

Cantor Fitzgerald

―

Buy

―

Reiterated

06/18/25

Cantor Fitzgerald Sticks to Their Buy Rating for Roivant Sciences (ROIV)

Dennis Ding

Jefferies

€15.62

Buy

-7.16%

Downside

Reiterated

03/11/25

Strategic Growth Potential in Roivant Sciences: Capitalizing on Graves' Disease Market and FcRn Indications

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Samantha Semenkow

Citi

€13.88→€21.69

Buy

28.95%

Upside

Reiterated

10/30/25

Roivant Sciences price target raised to $25 from $16 at CitiRoivant Sciences price target raised to $25 from $16 at Citi

Brian Cheng

J.P. Morgan

€17.35

Buy

3.16%

Upside

Reiterated

10/08/25

J.P. Morgan Reaffirms Their Buy Rating on Roivant Sciences (ROIV)

Corinne Johnson

Goldman Sachs

€20.82

Buy

23.79%

Upside

Reiterated

09/30/25

Goldman Sachs Sticks to Their Buy Rating for Roivant Sciences (ROIV)

David Risinger

Leerink Partners

€15.62→€19.09

Buy

13.47%

Upside

Reiterated

09/29/25

Analysts Offer Insights on Healthcare Companies: Roivant Sciences (NASDAQ: ROIV), Climb Bio (NASDAQ: CLYM) and Crinetics Pharmaceuticals (NASDAQ: CRNX)

Chi Meng Fong

Bank of America Securities

€14.31

Hold

-14.90%

Downside

Reiterated

09/24/25

Hold Rating for Roivant Sciences Amid Promising Developments and Competitive Challenges

Yaron Werber

TD Cowen

€19.95

Buy

18.63%

Upside

Reiterated

09/18/25

Yaron Werber's Buy Rating Highlights Brepocitinib's Potential as a Leading Treatment for Dermatomyositis

Douglas Tsao

H.C. Wainwright

€15.62→€17.35

Buy

3.16%

Upside

Reiterated

09/18/25

H.C. Wainwright Reaffirms Their Buy Rating on Roivant Sciences (ROIV)

Yatin Suneja

Guggenheim

€13.01→€18.22

Buy

8.31%

Upside

Reiterated

09/17/25

Guggenheim Keeps Their Buy Rating on Roivant Sciences (ROIV)

Prakhar Agrawal

Cantor Fitzgerald

―

Buy

―

Reiterated

06/18/25

Cantor Fitzgerald Sticks to Their Buy Rating for Roivant Sciences (ROIV)

Dennis Ding

Jefferies

€15.62

Buy

-7.16%

Downside

Reiterated

03/11/25

Strategic Growth Potential in Roivant Sciences: Capitalizing on Graves' Disease Market and FcRn Indications

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Roivant Sciences

1 Month

xxx

Success Rate

11/15 ratings generated profit

Average Return

+7.21%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 73.33% of your transactions generating a profit, with an average return of +7.21% per trade.

3 Months

xxx

Success Rate

12/15 ratings generated profit

Average Return

+20.95%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +20.95% per trade.

1 Year

Douglas TsaoH.C. Wainwright

Success Rate

21/23 ratings generated profit

Average Return

+46.72%

reiterated a buy rating 2 months ago

Copying Douglas Tsao's trades and holding each position for 1 Year would result in 91.30% of your transactions generating a profit, with an average return of +46.72% per trade.

2 Years

xxx

Success Rate

23/23 ratings generated profit

Average Return

+72.93%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +72.93% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

87S Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 87S has received 18 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. 87S average Analyst price target in the past 3 months is 18.60.

Each month's total comprises the sum of three months' worth of ratings.

87S Financial Forecast

87S Earnings Forecast

Next quarter’s earnings estimate for 87S is -€0.28 with a range of -€0.41 to -€0.21. The previous quarter’s EPS was -€0.22. 87S beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year 87S has Preformed in-line its overall industry.

87S Sales Forecast

Next quarter’s sales forecast for 87S is €4.88M with a range of €0.00 to €13.04M. The previous quarter’s sales results were €1.89M. 87S beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 87S has Preformed in-line its overall industry.

87S Stock Forecast FAQ

What is DE:87S’s average 12-month price target, according to analysts?

Based on analyst ratings, Roivant Sciences’s 12-month average price target is 18.60.

What is DE:87S’s upside potential, based on the analysts’ average price target?

Roivant Sciences has 10.58% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Roivant Sciences a Buy, Sell or Hold?

Roivant Sciences has a consensus rating of Strong Buy, which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.

What is Roivant Sciences’s share price target?

The average share price target for Roivant Sciences is 18.60. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €21.69 ,and the lowest forecast is €14.31. The average share price target represents 10.58% Increase from the current price of €16.82.

What do analysts say about Roivant Sciences?

Roivant Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of Roivant Sciences?

To buy shares of DE:87S, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Roivant Sciences (87S) Stock Forecast & Price Target

87S Analyst Ratings

87S Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Roivant Sciences

87S Analyst Recommendation Trends

87S Financial Forecast

87S Earnings Forecast

87S Sales Forecast

87S Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts